Axel Grothey, MD, West Cancer Center & Research Institute

home / authors / axel-grothey-md-west-cancer-center

Articles

Future Directions in Later Line Therapy for mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Key Trials in mCRC: I/O Combination Therapies

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Role of I/O Combination Therapies in mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Using I/O in MSI-H Tumors in mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Sequencing in mCRC: Later-Line Therapies

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

$Therapeutic Agents in Relapsed/Refractory mCRC$

Therapeutic Agents in Relapsed/Refractory mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

CORRECT, RECOURSE, and ReDOS Trials in mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Later Lines of Therapy for mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Second-Line Treatment for mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Initiating Therapy for mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Continuum of Care for Metastatic CRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Belantamab Mafodotin Significantly Extends PFS vs Daratumumab in Myeloma

Dr Vogel on Updated OS Data for Frontline Camrelizumab Plus Rivoceranib in Unresectable HCC

Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512